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Many research groups reported on the relation between circulating tumor cells (CTCs) in peripheral blood and worse prognosis
for metastatic cancer patients. These results are based on CTCs counting and did not take into account molecular characteristics
of cells. To establish CTCs as a reliable and accurate biological marker, new technologies must be focused on CTC subpopulations:
dediﬀerentiated circulating tumor cells (ddCTCs) arising from epithelial mesenchymal transition (EMT). To select and detect
them, diﬀerent methods have been proposed but none has still reached the goal. Technical progress and translational research are
expected to establish CTCs as a real marker. Thus CTC evaluation proﬁling for each patient will lead to personalize followup and
therapy.
1.Introduction
Human cells can be classiﬁed as either epithelial or mes-
enchymal and are molecularly characterized by speciﬁc ex-
pressionofgenes.Inearlyembryonicmorphogenesis,epithe-
lial cells give rise to mesenchymal cells by a reversible
reaction, epithelial mesenchymal transition (EMT), between
the two phenotypes. Analogous cell status modiﬁcation is
observed in human cancer cells [1–3]. Numerous studies
have established a link between EMT markers in primary
tumor cells and aggressive clinical behaviour [4, 5]. Spread
of epithelial tumors to an anatomically distant site seems
to occur almost totally via the process of hematogeneous
dissemination [6, 7]. Moreover, the initiation of metastasis
may be an early event in tumor biology. Circulating tumor
cells (CTCs) have been postulated to be critical to this
process. In 1869, Ashworth discovered analogous cells to
those of a primary tumour in the postmortem patient’s
blood and named them Circulating Tumor Cells [8]. Today,
the term CTC encompasses all types of cells, which are
considered as foreign entities in the blood having some can-
cerous characters. Evidence has emerged that CTCs present a
heterogeneity as the one described for primary tumor cells.
Among CTC subpopulations, cancer stem and mesenchymal
cells have to be taken into account. We proposed to name
these cells dediﬀerentiated circulating tumor cells (ddCTCs).
CTC analysis is generally based on numeration, which is
considered to have a prognostic value, and the CellSearch
system (Veridex corporation, USA) has been cleared by
FDA as an aid to monitor patients with metastatic breast,
prostate, and colon cancer [17–19]. The surface epithelial
cell adhesion molecule (EpCAM) identiﬁes epithelial cells
circulating within the blood. Cells lacking CD45 but express-
ing cytokeratins (CK8, CK18, and CK19) are identiﬁed
as CTCs. This analytical method is able to predict free
disease and overall survival but cells arising from EMT
often escape detection [20]. Apart from counting, molecular
characterization of CTCs is of interest for larger purposes.
Other methods better isolate cell subpopulations having
key roles in metastatic process. We focus our review on
these analytical developments and their use for an accurate
characterization of ddCTCs.
2. EpithelialMesenchymal Transition
EMT is a morphogenetic process in which cells lose their
epithelial characteristics and gain mesenchymal proper-
ties during embryogenesis, wound healing, and carcinoma2 ISRN Oncology
invasion and acquire a ﬁbroblast-like morphology. These
mesenchymal cells may revert to an epithelial phenotype
allowing growth of metastasis [21]. It remains to be proved
that all the genes involved in physiological EMT pathways
are implemented in carcinoma cells migration. Vazquez-
Martin et al. demonstrated that EMT status rather than EMT
functioning establishes stemness [22]. They indicated that
overexpression of some EMT regulators may be suﬃcient to
eﬃcientlygeneratethebreastcancerstemcellphenotype and
their inhibition reduces mammospheres formed by MDA-
MD-231 cells growing in sphere medium. Thus, aberrant
disrupted signaling pathways sustain cancer cell division and
tumor growth. Thereby their results suggest that epithelial
cancer cells go astray to acquire motility, therapeutic resis-
tance, and stemness characters without driving a complete
EMT program. This could explain the diversity of CTC
subpopulations.
Some cells leave the primary tumor after EMT, migrate
separately, and look like mesenchymal cells. To borrow such
a way, there are modiﬁcations of protein structures im-
plicated in cell junctions: tight junctions, adherens junc-
tions, desmosomes, and gap junctions. The latter kept cells
together, unlike to mesenchymal cells that interact with their
neighbours only at focal contact without forming layers.
Other migrating cells can have unsteady phenotype, which
corresponds to a partial EMT characterized by maintenance
ofcell-celladhesionstructuresthatdonotprecludeactivecell
migration. Therefore, new detection methods must take into
account the diversity of circulating cell subsets and relevant
markershavetobedeveloped[23].Untilnow,qualityofCTC
analyseshasbeenbiasedbycurrentlyusedenrichmentmeth-
ods. Protocols often rely on marker expressions (EpCAM,
cytokeratins) possibly leading to a loss of less diﬀerentiated
tumor cells. Cells obtained by EpCAM enrichment are het-
erogeneous and those not expressing epithelial markers can
bedetectedbyusingEMT-likecharacteristics[24].Moreover,
some cells lack EpCAM expression and are missed when
CTCs are captured with solely EpCAM-based technology
[25].Owingtothissubpopulationdiversity,useofmorethan
one antibody is a necessity.
3. Mesenchymal and Cancer Stem Cells
Ontogeny of cancer stem cell-like has not been fully delin-
eated. EMT status mediates invasive chemo/radioresistance
properties and mesenchymal morphology of cancer cells. It
endows cells with stemness features. These dediﬀerentiated
cells were initially described in breast cancer by Al-Hajj et
al.[26].TheirhallmarkisCD44+/CD24−/low immunopheno-
type. However, Meyer et al. demonstrated that such cells can
give rise to CD44+/CD24+ populations with tumor initiating
potential [27]. Some authors noticed that the stemness
character of cancer cells is detected by ALDH1 expression
[28]. These results underline the diﬃculty to classify the
subsets of dediﬀerentiated cells. Numerous studies described
epithelial tumors as a mixture of cell clones, and so, such an
heterogeneity must be found among CTCs.
EMT is promoted by several signaling pathways:
TGFβ,W n t ,N o t c h ,h e d g e h o g ,a n dg r o w t hf a c t o r s[ 29–
34]. They converge towards induction of transcriptional
factors (Snail1, Slug, ZEB1 ZEB2, E47, and Twist), which
suppress E-cadherin expression [35, 36]. In epithelial cells,
β-catenin colocalizes with E-cadherin at cytoplasmic mem-
brane and enables the link between adherens junctions and
actin cytoskeleton. When E-cadherin is lowered, β-catenin
translocates to nucleus and participates to transcriptional
regulation of EMT. In EMT regulation, β-catenin plays a
central role. When E-cadherin is downloaded, cells express
N-cadherin,aproteinthatisassociatedtomigrationinvasion
and metastasis [37]. Some properties of mesenchymal cells
are issued from PI3Kase/Akt pathway, such as resistance
to apoptosis and proliferation eﬀects [38, 39]. Isoforms
of Akt control EMT and stem cell renewal, regulations
depending on the equilibrium between isoforms 1 and 2
rather than on the total Akt. The activity of Akt is negatively
regulated by PTEN (Phosphatase and Tensin Homologue).
PTEN/PI3Kase/Akt pathway seems to be a promising target
in the treatment of breast cancer patients [40, 41]. A special
focus has to be made on Twist and BMI1. These two
proteins are essential in induction, maintenance of EMT, and
acquisition of stemness by mesenchymal cells (BMI1 is a
polycomb group protein that maintains self-renewal). Yang
et al. suggested that Twist1 and BMI1 cooperatively act to
promote cancer dediﬀerentiation and metastasis [42]. They
demonstrated that BMI1 suppression upregulates p16INK4a
expressionandreducesCD44+,ALDH +,andsidepopulation
cells leading to decrease tumorosphere formation.
MicroRNAs (small 19–22 nucleotides long noncoding
RNA) that inhibit gene expression at the posttranscriptional
level are implicated in EMT and stemness. Among them,
mir200c seems to be a pivotal one [43, 44]. ZEB1 and
ZEB2, EMT mediators, are targeted by mir200c. Moreover,
it negatively regulates BMI1 involved in self-renewal of stem
cells. Another microRNA, like let-7, plays major roles in
invasion metastasis and dediﬀerentiation of cancer cells [45].
This burst of research and results concerning mesenchy-
mal and cancer stem cells essentially devoted to primary
tumors and cancer cell lines led numerous laboratories to
startatranslationalresearchonthistypeofcellsintheblood.
4.ComparativeAnalysesof
CTC Subpopulations
New described methods propose molecular characterization
of cells. They diﬀer from those limited to numeration, which
only bring information about the prognosis. They would
be able to establish an accurate assessment of the residual
disease and to develop personalized therapy. The followup of
these ddCTCs in the blood might be essential to test eﬃcacy
in novel drug trials. In this context, we discuss major recent
publications taking into account the EMT aspect for CTC
analysis, even if they only studied a few number of markers.
Quoted data are summarized in Table 1.
Aktas et al. described that tumor cells spreading from the
primary tumor into the circulation may undergo phenotypicISRN Oncology 3
Table 1: EMT-derived ddCTC. ddCTC patterns from epithelial diﬀerentiation to mesenchymal phenotype are summarized by data reported
in quoted publications. Epithelial and mesenchymal markers can be coexpressed.
Authors Cell enrichment and technology
Analysed characteristics of CTC subpopulations
Epithelial Mesenchymal Stemness
Aktas et al. [9] AdnaGen and RTPCR
Density gradient centrifugation Twist1, AKT2, PI3Ka ALDH1
CD44+/CD24−low
Theodoropoulos et al.
[10]
Cytospin,
Immunoﬂuorescence microscopy CK ALDH1
Armstrong et al. [11] CellSearch EpCAM, CK,
E cadherin
Vimentin,
Ncadherin, O cadherin CD133
Kallergi et al [12]
Density gradient centrifugation
Cytospin and confocal
microscopy
CK Twist1, Vimentin
Lecharpentier et al.
[13] ISET ﬁltration panCK Vimentin
Mego et al [14] Depletion of EpCAM
and CD45+cells RTPCR
Twist, SNAIL1, SLUG
ZEB1, FOXC2
Pecot et al. [15] Microchannel platform CK Vimentin, Twist
Ncadherin, SNAIL
Barri` ere et al. [16] AdnaGen and RTPCR Twist1, AKT2, PI3Ka ALDH1
BMI1, CD44
changes known as EMT [9]. They evaluated 226 blood
samples of 39 metastatic breast cancer (MBC) patients
during the followup of palliative chemo-, antibody-, or
hormonal-, therapy. The test required the enrichment of
CTCs from blood by using AdnaGen technology (AdnaGen
AG, Langenhagen, Germany) with a special washing proce-
dure. A singleplex PCR assay for ALDH1 and a multiplex
PCR for EMT markers (Twist1, Akt2, PI3Kα)w e r eu s e d .
Theyshowed thatEMT characteristics aredetectablein some
CTCs analyzed in MBC samples, suggesting a negative prog-
nostic impact as EMT switch leads to decreased apoptosis
and to the development of chemoresistance. Furthermore,
overexpression of ALDH1 in substantial number of their
samples demonstrated that CTCs often display stemness.
Their results underlined the diversity of subpopulations but
the classiﬁcation of CTC patterns seems not very clear.
Theodoropoulos et al. assessed the expression of CD44,
CD24, and ALDH1 on cytokeratin positive CTC of 30 pa-
tients with MBC using triple-marker immunoﬂuorescence
combined with confocal microscopy [10]. They reported
the presence of CD44+/CD24−/low and ALDH1high/CD24low
CTCs. Their cytological method enables characterization
of individual CTC and seems to be speciﬁc and sensitive;
nevertheless, this research approach is not feasible for daily
practice.
The high frequency of CTC coexpressing epithelial,
mesenchymal,andstemcellsmarkershasbeendemonstrated
by Armstrong et al. [11]. CTCs were processed by using
the CellSearch EpCAM-based immunocapture method, and
expression of some epithelial, mesenchymal, and stemness
markers was studied. In patients with metastatic castration-
resistant prostate cancer, Epcam, cytokeratins, and E-
cadherin were simultaneously expressed with vimentin, N-
cadherin, O-cadherin, and a stem cell marker CD133. They
equally found coexpression of cytokeratins, vimentin, and
N-cadherin in CTCs of MBC. Thus they demonstrated that
CTCs are solely not a population but exist in diﬀerent
transitional states from epithelial to stem cells.
The expression of Twist and vimentin in CTCs of
patients with early breast cancer or MBC was studied by
Kallergi et al. [12]. This investigation was done by double
immunoﬂuorescence on isolated peripheral blood mononu-
clearcellcytospinsusinganti-CKanti-Twistoranti-vimentin
antibodies. Triple staining revealed that all CK+/Twist+ or
CK+/vimentin+ cells were also CD45−. As others, these
authors demonstrated that both mesenchymal and epithelial
markers can be coexpressed in a same cell. The particularity
of their experiment lies on the use of negative selection
procedure for CTC isolation. Before cytospin, blood is
incubated with Dynal CELLection coated with anti-CD45
antibody.Twistandvimentinmarkers,suggestingEMT,were
identiﬁed more often in patients with metastatic disease than
in early-stage breast cancer. This fact supports that EMT is
involved in the invasive potential of CTCs.
A hybrid (epithelial/mesenchymal) phenotype of CTCs
was also demonstrated by Lecharpentier et al. in patients
with metastatic non-small-cell lung cancer (NSCLC) [13].
Enrichment of cancer cells was made by blood ﬁltration
using ISET methodology. They are triply labelled with
ﬂuorescent anti-vimentin, anti-pan-keratin antibodies, and
SYTOX orange nuclear dye. This publication showed for
the ﬁrst time the existence of CTCs with an epithelial
mesenchymal phenotype in patients with NSCLC.
To test eﬃcacy of neoadjuvant therapy, Mego et al.
studied the expression levels of EMT-inducing transcription
factors: Twist1, SNAIL1, SLUG, ZEB1, and FOXC2 in CD45-
negative CTCs [14]. They demonstrated that 15% of patients
with primary breast cancer overexpressed at least one of
the EMT markers and that any of these markers was more
likely to be detected for patients who received neoadjuvant4 ISRN Oncology
therapies than those who did not receive. Thus their results
underlined that CTCs with EMT phenotype may occur in
the peripheral circulation of patients with primary breast
cancer. Although there was no statistical correlation between
the overexpression of any EMT transcription factors and the
presence of CTCs detected by either CellSearch or AdnaTest,
theyshowedthatCTC-positivepatientsdetectedbythesetwo
methods had a higher tendency to overexpress EMT markers
comparedtopatientswithnoCTCs.Onceagain,theseresults
target the heterogeneity of CTC population.
Pecot et al. demonstrated that EMT-derived CTC popu-
lations are likely missed by current techniques and proposed
to explore new methods beyond the use of EpCAM and
CK-based antibody platforms for capturing and detecting
previously unrecognized CTC subpopulations [15].
In a recent experiment, we detected ddCTCs in patients
with early breast cancer diagnosis [16]. Blood analysis for 61
patients has been performed before any therapy at baseline
diagnosis. Three phenotypes were distinguished and char-
acterized by EMT markers (Twist, PI3Kα, Akt-2), stemness
markers (ALDH1, Bmi1, CD44), or a mixture of the two
previous ones. AdnaGen method was used for enrichment
cell selection, and ddCTCs were characterized by RT-PCR.
Among 61 included patients, 21 (39%) were positive for
ddCTCs. Statistical results indicated a relationship between
axillary node invasion and detection of ddCTCs but the
signiﬁcance level had a borderline value (P = 0.05). None
of these patients apart one showed epithelial circulating
cells. It is the ﬁrst time that ddCTC presence in the
blood is demonstrated with such a high rate at least when
the primary breast tumor is diagnosed without metastasis.
We demonstrated that EMT, leading to mesenchymal and
stemness phenotypes of CTCs, is an early event in the
dissemination process.
5. Perspectives for CTC Isolation
andCharacterization
Study of publications dealing with CTC indicates that
the lack of standardization of technology hampers the
implementation of CTC measurement in clinical routine
practice. Some major biological issues are still unresolved.
Epithelial cell-surface markers are widely used to trap CTC.
Enrichment steps are necessary to increase isolation success
rate. In positive selection by immunomagnetic beads, the
antibody mostly coated is EpCam. The latter may not
be optimal for detecting a heterogeneous population of
CTCs including those with a mesenchymal phenotype. To
overcome this failure, it seems to us that use of a bead
mixture coated with diﬀerent antibodies is more eﬃcient.
Research on speciﬁc cancer cell antigens could improve
the selectivity of the enrichment step. Moreover, depletion
of hematopoietic cells may help to avoid false positive
results due to illegitimate expression of mesenchymal or
stemness markers [46–49]. The important technical issue is
to expand CTC usefulness by increasing the speciﬁcity of
results leading to establish a real clinical monitoring. In case
a combination of speciﬁc antibodies against cancer cells can
be used, it would allow a better step of enrichment able
to capture epithelial, mesenchymal, and cancer stem cells.
Thereafter, cell sorting by dielectrophoresis would enable
to qualify each single cell at the molecular level [50]. This
improvement would conduct to establish a personalized
proﬁle for patients. The latter can thus be done by qRTPCR
of EMT and/or stemness markers, as now qRTPCR is
feasible on a single cell [51]. Such new technologies would
demonstrate the potential value of CTCs as markers in the
clinical management of cancer.
6. Conclusion
Themultiplicityofmethodsdescribedintheliteratureshows
h o wi ti sd i ﬃcult to analyse CTCs and no method has
still been endorsed by FDA. To establish CTCs as powerful
markers in oncology, optimization and standardization of
technologies, based on physics and molecular biology, is
essential for precise and reproducible determination. A
marker must be an indicator able to measure and evaluate
a normal or pathological biological process. If this goal is
reached, CTCs would be qualiﬁed as a biological marker. A
standardized method for CTC analyses would contribute to
establish a personalized medicine and to cope with patients
in oncology.
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